Petros Pharmaceuticals annual stock-based compensation
2021
2022
2023
2024
2025
Petros Pharmaceuticals Stock-Based Compensation Growth & History (PTPI)
Petros Pharmaceuticals's stock-based compensation was $304,634 for fiscal 2025.
View full Petros Pharmaceuticals company overviewPetros Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $304,634 | $107,419 | +54.47% |
| 2024 | 2024-12-31 | $197,215 | −$220,015 | −52.73% |
| 2023 | 2023-12-31 | $417,230 | −$777,846 | −65.09% |
| 2022 | 2022-12-31 | $1.2M | −$110,074 | −8.43% |
| 2021 | 2021-12-31 | $1.3M | — | — |
Petros Pharmaceuticals quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $117,906 | $43,585 | +58.64% |
| Q1 2026 | 2026-03-31 | $120,319 | $40,281 | +50.33% |
| Q4 2025 | 2025-12-31 | $75,138 | $75,138 | — |
| Q3 2025 | 2025-09-30 | $75,137 | $75,137 | — |
| Q2 2025 | 2025-06-30 | $74,321 | $57,487 | +341.49% |
| Q1 2025 | 2025-03-31 | $80,038 | −$100,343 | −55.63% |
| Q4 2024 | 2024-12-31 | $0 | −$212,738 | — |
| Q3 2024 | 2024-09-30 | $0 | −$30,840 | — |
| Q2 2024 | 2024-06-30 | $16,834 | −$26,482 | −61.14% |
| Q1 2024 | 2024-03-31 | $180,381 | $50,045 | +38.40% |
| Q4 2023 | 2023-12-31 | $212,738 | −$16,107 | −7.04% |
| Q3 2023 | 2023-09-30 | $30,840 | −$277,298 | −89.99% |
| Q2 2023 | 2023-06-30 | $43,316 | −$258,949 | −85.67% |
| Q1 2023 | 2023-03-31 | $130,336 | −$225,492 | −63.37% |
| Q4 2022 | 2022-12-31 | $228,845 | −$85,429 | −27.18% |
| Q3 2022 | 2022-09-30 | $308,138 | $254,971 | +479.57% |
| Q2 2022 | 2022-06-30 | $302,265 | −$288,237 | −48.81% |
| Q1 2022 | 2022-03-31 | $355,828 | $8,621 | +2.48% |
| Q4 2021 | 2021-12-31 | $314,274 | — | — |
| Q3 2021 | 2021-09-30 | $53,167 | — | — |
| Q2 2021 | 2021-06-30 | $590,502 | — | — |
| Q1 2021 | 2021-03-31 | $347,207 | — | — |
Petros Pharmaceuticals stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Petros Pharmaceuticals's stock-based compensation decreased from $1.3M to $304,634, a change of −$1.0M. The latest reported quarter, Q2 2026, shows $117,906.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Petros Pharmaceuticals source filings ↗